Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
2(22%)
Results Posted
100%(4 trials)
Terminated
2(22%)

Phase Distribution

Ph not_applicable
6
67%
Ph phase_2
2
22%
Ph early_phase_1
1
11%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 2Efficacy & side effects
2(22.2%)
N/ANon-phased studies
6(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(4)
Terminated(2)
Other(1)

Detailed Status

Completed4
Terminated2
unknown1
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (11.1%)
Phase 22 (22.2%)
N/A6 (66.7%)

Trials by Status

terminated222%
unknown111%
active_not_recruiting111%
completed444%
recruiting111%

Recent Activity

2 active trials
Showing 5 of 9
active_not_recruitingnot_applicable

DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

NCT03115333
recruitingphase_2

Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial

NCT06319027
terminatedphase_2

Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors

NCT00659126
unknownnot_applicable

Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors

NCT02526511
completedearly_phase_1

DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors

NCT00978562
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT03115333Not Applicable

DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

Active Not Recruiting
NCT06319027Phase 2

Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial

Recruiting
NCT00659126Phase 2

Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors

Terminated
NCT02526511Not Applicable

Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors

Unknown
NCT00978562Early Phase 1

DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors

Completed
NCT00103038Not Applicable

Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases

Completed
NCT02359097Not Applicable

Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma

Completed
NCT02269111Not Applicable

Quantitative MRI in Assessing Disease in Patients With Brain Tumors

Terminated
NCT00660543Not Applicable

MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy

Completed

All 9 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
9